IbisVision: Funding, Investors & Team (Oct 2026)
Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage is detected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment. The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test. The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times.
IbisVision has raised $5.6M across 1 funding round on record, the most recent an undisclosed round of $5.6M announced in May 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
IbisVision Company Profile and Key Stats
Latest funding round on record: May 2023.
IbisVision Funding Rounds
IbisVision Founders and Leadership Team
Contact details for the IbisVision team: 1 of 1 has an email address on file.
Start 14-day free trial →IbisVision Funding Compared to Other Biotechnology Startups
IbisVision's latest round of $5.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like IbisVision in Biotechnology and Newhouse
Companies Similar to IbisVision
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IbisVision Funding FAQs
What does IbisVision do?
Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage is detected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment. The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test. The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times.
How much funding has IbisVision raised?
IbisVision has raised $5.6M across 1 round on record. The most recent is an undisclosed round of $5.6M announced in May 2023.
When did IbisVision last raise funding?
IbisVision's most recent funding round on record is an undisclosed round of $5.6M, announced in May 2023.
Who founded IbisVision?
FundedIQ lists Justin Birley (Founder) at IbisVision.
Where is IbisVision headquartered?
IbisVision is based in Newhouse, North Lanarkshire, United Kingdom.
How many employees does IbisVision have?
IbisVision is in the 1-10 employee band.
How does IbisVision's funding compare to other Biotechnology startups?
IbisVision's latest round of $5.6M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's IbisVision Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for IbisVision is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.